Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 3,129 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the transaction, the insider now owns 54,826 shares in the company, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Kymera Therapeutics Trading Down 4.1 %

Shares of Kymera Therapeutics stock opened at $39.90 on Tuesday. The company has a 50 day moving average of $44.49 and a 200-day moving average of $43.88. Kymera Therapeutics, Inc. has a 1-year low of $25.02 and a 1-year high of $53.27. The company has a market cap of $2.58 billion, a PE ratio of -17.05 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm’s revenue was down 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.90) EPS. Research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Values First Advisors Inc. bought a new position in Kymera Therapeutics in the 3rd quarter valued at approximately $61,000. Quarry LP bought a new position in Kymera Therapeutics in the 3rd quarter valued at approximately $95,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new position in Kymera Therapeutics in the 2nd quarter valued at approximately $139,000. Finally, Quest Partners LLC increased its position in Kymera Therapeutics by 1,402.0% in the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after acquiring an additional 4,865 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KYMR. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. UBS Group cut their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a report on Monday, November 4th. Guggenheim boosted their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st. BTIG Research began coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, Leerink Partners reissued an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.38.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.